BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32362603)

  • 1. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
    J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary central nervous system lymphoma in immunocompetent patients: A regional cancer center experience.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
    South Asian J Cancer; 2017; 6(4):165-168. PubMed ID: 29404295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
    Chen C; Sun P; Cui J; Yan S; Chen H; Xia Y; Bi X; Liu P; Wang Y; Yang H; Nie M; Zhang XW; Jiang W; Li ZM
    Cancer Med; 2019 Apr; 8(4):1359-1367. PubMed ID: 30821418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
    Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
    Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
    Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
    Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
    Wang H; Wang M; Wei J; Wang L; Mao L; Jin J
    J Int Med Res; 2018 Feb; 46(2):883-894. PubMed ID: 28984175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment for primary CNS lymphoma: the next step.
    Abrey LE; Yahalom J; DeAngelis LM
    J Clin Oncol; 2000 Sep; 18(17):3144-50. PubMed ID: 10963643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
    Kim N; Lim DH; Yoon SE; Kim SJ; Kim WS
    J Neurooncol; 2021 Sep; 154(2):207-217. PubMed ID: 34331673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
    Laack NN; O'Neill BP; Ballman KV; O'Fallon JR; Carrero XW; Kurtin PJ; Scheithauer BW; Brown PD; Habermann TM; Colgan JP; Gilbert MR; Hawkins RB; Morton RF; Windschitl HE; Fitch TR; Pajon ER;
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):476-82. PubMed ID: 20800387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.
    Velasco R; Mercadal S; Vidal N; Alañá M; Barceló MI; Ibáñez-Juliá MJ; Bobillo S; Caldú Agud R; García Molina E; Martínez P; Cacabelos P; Muntañola A; García-Catalán G; Sancho JM; Camro I; Lado T; Erro ME; Gómez-Vicente L; Salar A; Caballero AC; Solé-Rodríguez M; Gállego Pérez-Larraya J; Huertas N; Estela J; Barón M; Barbero-Bordallo N; Encuentra M; Dlouhy I; Bruna J; Graus F;
    J Neurooncol; 2020 Jul; 148(3):545-554. PubMed ID: 32524392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
    Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
    J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma.
    Bessell EM; Graus F; López-Guillermo A; Villá S; Verger E; Petit J; Holland I; Byrne P
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):457-64. PubMed ID: 11380234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
    Illerhaus G; Marks R; Müller F; Ihorst G; Feuerhake F; Deckert M; Ostertag C; Finke J
    Ann Oncol; 2009 Feb; 20(2):319-25. PubMed ID: 18953065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
    Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience.
    Ney DE; Reiner AS; Panageas KS; Brown HS; DeAngelis LM; Abrey LE
    Cancer; 2010 Oct; 116(19):4605-12. PubMed ID: 20572045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009.
    Shibamoto Y; Sumi M; Takemoto M; Tsuchida E; Onodera S; Matsushita H; Sugie C; Tamaki Y; Onishi H
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):653-60. PubMed ID: 25034088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
    Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
    Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
    Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.